Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing SALT LAKE CITY,…
Month: September 2023
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing SALT LAKE CITY,…
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
Full ENVASARC accrual expected in Q4 and final data expected in mid-2024 SAN DIEGO, Sept….
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
Full ENVASARC accrual expected in Q4 and final data expected in mid-2024 SAN DIEGO, Sept….
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs
– Seasoned biopharma medical leader joins Apnimed as it initiates its Phase 3 clinical program…
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs
– Seasoned biopharma medical leader joins Apnimed as it initiates its Phase 3 clinical program…
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology…
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology…
Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference
Morgan Stanley Fireside Chat Replay Now Available SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) —…
Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference
Morgan Stanley Fireside Chat Replay Now Available SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) —…
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
Enables the efficient expansion of surface targets for radioisotope delivery INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept….
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
Enables the efficient expansion of surface targets for radioisotope delivery INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept….
Aptose to Present at the Cantor Global Healthcare Conference
SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or…
WSO2 Introduces WSO2 API Platform for Kubernetes
Built on a Kubernetes-native, microservice architecture, the WSO2 APK next-generation, open-source API management platform enables…
Arcadia Earth Scales Its Environmental Storytelling Platform With Extended Reality Experiences
NEW YORK–(BUSINESS WIRE)–Arcadia Earth, the next-generation environmental storytelling exhibition, announces the launch of its XR…
Personas Provides Further Update on Keek Marketing Launch
Toronto, Ontario–(Newsfile Corp. – September 18, 2023) – Personas Social Incorporated (TSXV: PRSN) (the “Company“) announces…
FloraWorks Announces Updated Analysis of Landmark Clinical Trial; CBN Shown Effective for Sleep
Radicle Science found TruCBN(TM) to significantly improve sleep outcomes in first-ever placebo-controlled trial of pure…
Defense Technologies International Corp. (DTII) Announces Sale and Shipment of Its ‘Passive Portal’ to Macon County School District
Del Mar, California–(Newsfile Corp. – September 18, 2023) – Defense Technologies International Corp. (OTC Pink:…
Datametrex Officially Launches AnalyticsGPT
Toronto, Ontario–(Newsfile Corp. – September 18, 2023) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB:…
Mio Ho Debuts SYLPH and SEXROSE in Vegas, Inspiring Customers’ Self-Empowerment
LAS VEGAS, NV, Sept 18, 2023 – (ACN Newswire) – When SYLPH and SEXROSE, two…